- Home
- DGLY vs REVB Comparison
DGLY vs REVB Comparison
Compare DGLY & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DGLY
- REVB
- Stock Information
- Founded
- DGLY 2004
- REVB 2020
- Country
- DGLY United States
- REVB United States
- Employees
- DGLY N/A
- REVB N/A
- Industry
- DGLY Radio And Television Broadcasting And Communications Equipment
- REVB Biotechnology: Pharmaceutical Preparations
- Sector
- DGLY Technology
- REVB Health Care
- Exchange
- DGLY Nasdaq
- REVB Nasdaq
- Market Cap
- DGLY 2.8M
- REVB 2.3M
- IPO Year
- DGLY N/A
- REVB N/A
- Fundamental
- Price
- DGLY $1.25
- REVB $0.87
- Analyst Decision
- DGLY
- REVB
- Analyst Count
- DGLY 0
- REVB 0
- Target Price
- DGLY N/A
- REVB N/A
- AVG Volume (30 Days)
- DGLY 39.9K
- REVB 121.2K
- Earning Date
- DGLY 12-29-2025
- REVB 11-06-2025
- Dividend Yield
- DGLY N/A
- REVB N/A
- EPS Growth
- DGLY N/A
- REVB N/A
- EPS
- DGLY N/A
- REVB N/A
- Revenue
- DGLY $19,097,965.00
- REVB N/A
- Revenue This Year
- DGLY N/A
- REVB N/A
- Revenue Next Year
- DGLY $7.38
- REVB N/A
- P/E Ratio
- DGLY N/A
- REVB N/A
- Revenue Growth
- DGLY N/A
- REVB N/A
- 52 Week Low
- DGLY $1.08
- REVB $0.83
- 52 Week High
- DGLY $1,960.00
- REVB $60.48
- Technical
- Relative Strength Index (RSI)
- DGLY 24.18
- REVB 25.66
- Support Level
- DGLY $1.20
- REVB $0.83
- Resistance Level
- DGLY $1.34
- REVB $0.91
- Average True Range (ATR)
- DGLY 0.10
- REVB 0.08
- MACD
- DGLY -0.03
- REVB 0.00
- Stochastic Oscillator
- DGLY 22.76
- REVB 10.03
About DGLY Digital Ally Inc.
Digital Ally Inc produces digital video imaging and storage products for use in law enforcement, security, and commercial applications. Its products are an in-car digital video/audio recorder contained in a rear-view mirror for use in law enforcement and commercial fleets. It can integrate electronic, radio, computer, and multi-media technologies to create solutions to address needs in a variety of other industries and markets, including mass transit, school buses, taxicab, and military. The company sells its products directly to law enforcement agencies, security organizations, and consumer and commercial fleet operators both domestically and internationally through third-party distributors. Its segments include Video Solutions, Revenue Cycle Management, and Entertainment.
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).